Ofatumumab is a human monoclonal antibody which appears to inhibit early-stage B lymphocyte activation. It is under development for treatment of certain B-cell cancers as well as rheumatoid arthritis (RA).

Clinical trial status

Status of clinical trials conducted by Genmab and GSK, as of late 2007.

• Chronic lymphocytic leukemia – Phase III
• relapsed follicular non-Hodgkin?s lymphoma (NHL) – Phase III
• Rheumatoid arthritis (RA):
  • Phase II – NCT00291928 – HuMax-CD20 in patients adult RA patients who have failed one or more DMARDs
  • Phase III – OFA110635/GEN410 – Ofatumumab in adult RA patients who have had an inadequate response to methotrexate
  • Phase III – OFA110634/GEN411 – Ofatumumab in adult RA patients who have had an inadequate response to TNF-alpha antagonist therapy
• Diffuse large B cell lymphoma (DLBCL) – Phase II

See also

• rituximab, a chimerical CD20 agonist
• ocrelizumab, a humanized (90%) CD20 agonist

Articles

• Coiffier B, Lepretre S, Moller Pedersen L, Gadeberg O, Fredriksen H, van Oers MH, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T, "Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A phase I-II study", Blood 2007 Nov 14

External links

• ClinicalTrials.gov - HuMax-CD20